Form 4: BioVie Inc. CFO Joanne Wendy Kim Reports Stock Option Grant

Chief Financial Officer of BioVie Inc., Joanne Wendy Kim, reports the acquisition of stock options.

Summary

• On December 20, 2024, Joanne Wendy Kim, the Chief Financial Officer of BioVie Inc., acquired 14,417 stock options with an exercise price of $1.90.
• These options vest in three equal installments on December 20, 2024, December 20, 2025, and December 20, 2026.
• Following the transaction, Ms. Kim directly owns 14,417 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of stock option grants to a key executive. It's a standard practice and doesn't inherently indicate positive or negative performance.

Positives

• The grant of stock options to the CFO aligns her interests with those of the shareholders.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders by incentivizing them to increase the company's stock value.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead Sciences, and Biogen routinely use stock options to incentivize their executives.
• The vesting schedule of three years is also typical, aligning with industry norms for long-term performance incentives.

Stakeholder Impact

• The stock option grant could potentially incentivize the CFO to improve company performance, benefiting shareholders.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates